Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aripiprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 20/20 | 0.98 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.98 |
| ▸ | DRD3 | P35462 | 5/20 | 0.98 |
| ▸ | DRD4 | P21917 | 4/20 | 0.98 |
| ▸ | HTR2B | P41595 | 3/20 | 0.98 |
| ▸ | DRD1 | P21728 | 2/20 | 0.98 |
| ▸ | DRD5 | P21918 | 2/20 | 0.98 |
| ▸ | HTR2C | P28335 | 2/20 | 0.98 |
| ▸ | HTR7 | P34969 | 2/20 | 0.98 |
| ▸ | HTR6 | P50406 | 2/20 | 0.98 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | HTR3B | O95264 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | ESR1 | P03372 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aripiprazole SCHEMBL29935430 | 1.00 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29475638 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29438823 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL982189 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29356997 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL8255 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29475637 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL7097505 | 0.98 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL236666 | 0.98 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL5147095 | 0.98 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108069900-B | Preparation method and application of aripiprazole hydrochloride | 齐鲁制药有限公司 | 2022-09-23 | — | — | CN | claimed |
| CN-108069900-A | The preparation method and purposes of Aripiprazole hydrochloride | 齐鲁制药有限公司 | 2018-05-25 | — | — | CN | claimed |
| US-20100204470-A1 | METHOD FOR SALT PREPARATION | SANDOZ AG | 2010-08-12 | — | — | US | claimed |
| US-20100113784-A1 | PROCESS FOR PREPARING CRYSTALLINE ARIPIPRAZOLE | CADILA HEALTH CARE LIMITED (IN) | 2010-05-06 | — | — | US | claimed |
| EP-2084133-A2 | PROCESS FOR PREPARING CRYSTALLINE ARIPIPRAZOLE | Cadila Healthcare Limited (IN) | 2009-08-05 | — | — | EP | claimed |
| EP-2032521-A2 | NEW METHOD FOR SALT PREPARATION | Sandoz AG (CH) | 2009-03-11 | — | — | EP | claimed |
| US-20080182856-A1 | Characterized by x-ray powder diffraction pattern having peaks expressed as 2 theta at 6.2, 8.5, 11.5, 15.2, 15.5, 16.8, 17.2, 18.3, 18.9, 19.6, 20.6, 21.3, 23.4, 24.1, 24.7, 25.9, 27.5, 28.3, 28.9, 32.8 degrees; preparation via crystal form of hydrochloride serves in producing pure aripiprazole | HETERO DRUGS LIMITED (IN) | 2008-07-31 | — | — | US | claimed |
| WO-2008059518-A2 | PROCESS FOR PREPARING CRYSTALLINE ARIPIPRAZOLE | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | claimed |
| US-20080085903-A1 | NOVEL CRYSTALLINE FORMS OF ARIPIPRAZOLE | HETERO DRUGS LIMITED (IN) | 2008-04-10 | — | — | US | claimed |
| US-20080086005-A1 | NOVEL CRYSTALLINE FORMS OF ARIPIPRAZOLE | HETERO DRUGS LIMITED (IN) | 2008-04-10 | — | — | US | claimed |
| WO-2008000418-A2 | NEW METHOD FOR SALT PREPARATION | SANDOZ AG (CH) | 2008-01-03 | — | — | WO | claimed |
| EP-1606262-A1 | NOVEL CRYSTALLINE FORMS OF ARIPIPRAZOLE | Hetero Drugs Limited (IN) | 2005-12-21 | — | — | EP | claimed |
| US-20050159429-A1 | Novel crystalline forms of aripiprazole | HETERO DRUGS LIMITED (IN) | 2005-07-21 | — | — | US | claimed |
| WO-2004083183-A1 | NOVEL CRYSTALLINE FORMS OF ARIPIPRAZOLE | HETERO DRUGS LIMITED (IN) | 2004-09-30 | — | — | WO | claimed |
| CN-116338030-A | Method for detecting antipsychotics and antidepressants in human milk by HPLC-MS/MS method | 厦门市仙岳医院(厦门市精神卫生中心、厦门医学院附属仙岳医院) | 2023-06-27 | — | — | CN | disclosed |
| CN-108069900-B | Preparation method and application of aripiprazole hydrochloride | 齐鲁制药有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-108069900-B | Preparation method and application of aripiprazole hydrochloride | 齐鲁制药有限公司 | 2022-09-23 | — | — | CN | disclosed |
| EP-0367141-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1996-01-10 | — | — | EP | disclosed |
| US-5006528-A | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-09 | — | — | US | disclosed |
| EP-0367141-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182856-A1 | Characterized by x-ray powder diffraction pattern having peaks expressed as 2 theta at 6.2, 8.5, 11.5, 15.2, 15.5, 16.8, 17.2, 18.3, 18.9, 19.6, 20.6, 21.3, 23.4, 24.1, 24.7, 25.9, 27.5, 28.3, 28.9, 32.8 degrees; preparation via crystal form of hydrochloride serves in producing pure aripiprazole | ADRA2C, YWHAQ, CYP2C18 | DRD2 273/4885HTR1A 84/4885HTR2A 56/4885 |
| US-20080085903-A1 | NOVEL CRYSTALLINE FORMS OF ARIPIPRAZOLE | ATG4A, ATG4B, CYP4F3 | DRD2 1403/4885HTR1A 130/4885HTR2A 82/4885 |
| US-20080086005-A1 | NOVEL CRYSTALLINE FORMS OF ARIPIPRAZOLE | ATG4A, ATG4B, CYP4F3 | DRD2 1403/4885HTR1A 130/4885HTR2A 82/4885 |
| US-20050159429-A1 | Novel crystalline forms of aripiprazole | ATG4A, ATG4B, CYP4F3 | DRD2 1403/4885HTR1A 130/4885HTR2A 82/4885 |
| US-20100113784-A1 | PROCESS FOR PREPARING CRYSTALLINE ARIPIPRAZOLE | CYP2F1, CYP3A5, CYP2A6 | DRD2 1618/4885HTR1A 390/4885HTR2A 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.